Viral Infections: Race against dengue
Understanding the kinetics of dengue viruses in the bloodstream can provide insights into the clinical outcomes of the disease.
- Department of Infectious Diseases, Singapore General Hospital, Singapore
- Duke-NUS Medical School, Singapore
- Viral Research and Experimental Medicine Centre, SingHealth Duke-NUS Academic Medical Centre, Singapore
- Department of Translational Clinical Research, Singapore General Hospital, Singapore
- Saw Swee Hock School of Public Health, National University of Singapore, Singapore
Dengue fever is an acute viral disease that afflicts an estimated 100 million people each year, killing around 40,000 of those infected (Bhatt et al., 2013). It can be caused by infection with any of the four different dengue viruses, so it is possible to catch the disease four times. Moreover, a primary infection can be followed by a secondary infection and, in some cases, post-secondary infections.
The geographic footprint of Aedes aegypti, the mosquito that transmits dengue viruses, covers the tropics and is expanding both northwards – it can now be found in northern California – and southwards (Pless et al., 2017). Globalization, urbanization and travel are the main drivers for the spread of the disease, which is undoubtedly going to worsen with climate change (Messina et al., 2019). There are currently no licensed antiviral drugs to treat dengue, and the two vaccines that have been licensed are of limited benefit, so as we wait for better vaccines and drugs, there is an urgent need to find new ways to combat dengue to complement existing efforts that target Aedes aegypti.
Dengue develops in phases. In the first two to three days after the onset of fever, dengue presents with symptoms similar to influenza and other viral infections. Around four to six days after onset, more dengue-specific symptoms – such as pain at the back of the eyes and decreased platelet count – become apparent. The critical phase of the illness occurs as the fever subsides: the risk of inflammation-driven vascular damage and leakage increases, and if this is not effectively managed, the result can be dangerously low blood pressure and multi-organ failure. When this happens, the fatality rate can be as high as 30%.
Higher levels of the viruses in the blood (also known as viremia) are thought to increase the severity of the disease. Lowering the amount of dengue virus in the bloodstream may, therefore, reduce the risk of severe dengue (Low et al., 2017). Now, in eLife, Nguyen Lam Vuong, Ronald Geskus and colleagues report how an antiviral drug might be able to alter the course of disease progression in dengue patients (Vuong et al., 2024). They also highlight the challenges that drug developers face.
Using pooled data from three studies conducted in Vietnam between 2000 and 2016, which included daily platelet counts and measurements of viremia for 2,340 dengue patients, Vuong et al. were able to reconstruct the kinetics of the different dengue viruses. In particular, the researchers were able to determine which type of dengue virus had been present and whether patients were experiencing a primary or secondary infection. Although they did not attempt to distinguish between secondary and post-secondary infections, most of the secondary dengue patients were likely experiencing their second infection, as the third and fourth infections are mostly asymptomatic (Olkowski et al., 2013).
The results of Vuong et al. – who are based at the Oxford University Clinical Research Unit Vietnam and other research institutes in Vietnam, the United Kingdom, the United States, Germany and Australia – show that viremia levels decreased rapidly following the onset of symptoms, depending on the type of virus, with dengue virus type-1 having the highest viremia levels in the first five to six days. High levels of viremia in the first two days following onset also correlated with a higher risk of severe dengue and risk of vascular leakage. In both primary and secondary infections, viremia levels of all four viruses decreased significantly after the first two days of fever, in correlation with the severity of the disease.
The results indicate that lowering viral levels could thus reduce the risk of vascular leakage and severe dengue. However, antiviral drugs would need to be highly potent in targeting viral replication to reduce viral levels faster than their natural decay rate. Antiviral treatment would likely also need to be given within the first two days following fever onset to effectively alter the course of the illness.
The ability to initiate treatment early also requires an early diagnosis, but it is difficult to differentiate between dengue and other viral fevers during the early stages of illness. Current point-of-care rapid tests detect the viral protein NS1 in the blood of dengue patients. However, this protein is less detectable in those with secondary infections (Chaterji et al., 2011): this is unfortunate because secondary infection is associated with a greater risk of severe dengue. This means that the use of current tests could thus, paradoxically, exclude many patients who need antiviral treatment.
To effectively target dengue fever, there is a need to develop both new drugs and new tests. While there are currently three highly promising drugs being tested in phases II and III of clinical trials, efforts to develop a low-cost rapid test that can accurately diagnose both primary and secondary infection are lacking. It would be a tragedy if – once licensed – antiviral drugs could not be given to dengue patients early enough to alter disease progression due to the lack of a suitable early diagnostic test.
References
-
Evaluation of the NS1 rapid test and the WHO dengue classification schemes for use as bedside diagnosis of acute dengue fever in adultsAmerican Journal of Tropical Medicine and Hygiene 84:224–228.https://doi.org/10.4269/ajtmh.2011.10-0316
-
Current status of dengue therapeutics research and developmentJournal of Infectious Diseases 215:S96–S102.https://doi.org/10.1093/infdis/jiw423
-
The current and future global distribution and population at risk of dengueNature Microbiology 4:1508–1515.https://doi.org/10.1038/s41564-019-0476-8
-
Reduced risk of disease during postsecondary dengue virus infectionsJournal of Infectious Diseases 208:1026–1033.https://doi.org/10.1093/infdis/jit273
-
Multiple introductions of the dengue vector, Aedes aegypti, into CaliforniaPLOS Neglected Tropical Diseases 11:e0005718.https://doi.org/10.1371/journal.pntd.0005718
Article and author information
Author details
Publication history
- Version of Record published: February 15, 2024 (version 1)
Copyright
© 2024, Kwek and Ooi
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 813
- views
-
- 82
- downloads
-
- 0
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Viral Infections: Race against dengue
eLife 13:e96018.
https://doi.org/10.7554/eLife.96018
Further reading
-
- Medicine
There is clear evidence that the sympathetic nervous system (SNS) mediates bone metabolism. Histological studies show abundant SNS innervation of the periosteum and bone marrow–these nerves consist of noradrenergic fibers that immunostain for tyrosine hydroxylase, dopamine beta-hydroxylase, or neuropeptide Y. Nonetheless, the brain sites that send efferent SNS outflow to the bone have not yet been characterized. Using pseudorabies (PRV) viral transneuronal tracing, we report, for the first time, the identification of central SNS outflow sites that innervate bone. We find that the central SNS outflow to bone originates from 87 brain nuclei, sub-nuclei, and regions of six brain divisions, namely the midbrain and pons, hypothalamus, hindbrain medulla, forebrain, cerebral cortex, and thalamus. We also find that certain sites, such as the raphe magnus (RMg) of the medulla and periaqueductal gray (PAG) of the midbrain, display greater degrees of PRV152 infection, suggesting that there is considerable site-specific variation in the levels of central SNS outflow to the bone. This comprehensive compendium illustrating the central coding and control of SNS efferent signals to bone should allow for a greater understanding of the neural regulation of bone metabolism, and importantly and of clinical relevance, mechanisms for central bone pain.
-
- Medicine
Rare early-onset lower urinary tract disorders include defects of functional maturation of the bladder. Current treatments do not target the primary pathobiology of these diseases. Some have a monogenic basis, such as urofacial, or Ochoa, syndrome (UFS). Here, the bladder does not empty fully because of incomplete relaxation of its outflow tract, and subsequent urosepsis can cause kidney failure. UFS is associated with biallelic variants of HPSE2, encoding heparanase-2. This protein is detected in pelvic ganglia, autonomic relay stations that innervate the bladder and control voiding. Bladder outflow tracts of Hpse2 mutant mice display impaired neurogenic relaxation. We hypothesized that HPSE2 gene transfer soon after birth would ameliorate this defect and explored an adeno-associated viral (AAV) vector-based approach. AAV9/HPSE2, carrying human HPSE2 driven by CAG, was administered intravenously into neonatal mice. In the third postnatal week, transgene transduction and expression were sought, and ex vivo myography was undertaken to measure bladder function. In mice administered AAV9/HPSE2, the viral genome was detected in pelvic ganglia. Human HPSE2 was expressed and heparanase-2 became detectable in pelvic ganglia of treated mutant mice. On autopsy, wild-type mice had empty bladders, whereas bladders were uniformly distended in mutant mice, a defect ameliorated by AAV9/HPSE2 treatment. Therapeutically, AAV9/HPSE2 significantly ameliorated impaired neurogenic relaxation of Hpse2 mutant bladder outflow tracts. Impaired neurogenic contractility of mutant detrusor smooth muscle was also significantly improved. These results constitute first steps towards curing UFS, a clinically devastating genetic disease featuring a bladder autonomic neuropathy.
